- Previous Close
163.85 - Open
163.10 - Bid 147.30 x --
- Ask 162.80 x --
- Day's Range
155.80 - 163.10 - 52 Week Range
155.80 - 265.80 - Volume
6,234 - Avg. Volume
23,595 - Market Cap (intraday)
22.338B - Beta (5Y Monthly) 1.51
- PE Ratio (TTM)
54.40 - EPS (TTM)
2.85 - Earnings Date Apr 16, 2025 - Apr 21, 2025
- Forward Dividend & Yield 0.85 (0.62%)
- Ex-Dividend Date Apr 28, 2023
- 1y Target Est
--
Vitrolife AB (publ) engages in development, production, and marketing of products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; Americas; and Asia. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is based in Gothenburg, Sweden.
www.vitrolife.comRecent News: 0YAY.IL
View MorePerformance Overview: 0YAY.IL
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0YAY.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0YAY.IL
View MoreValuation Measures
Market Cap
21.08B
Enterprise Value
22.03B
Trailing P/E
41.02
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.82
Price/Book (mrq)
1.54
Enterprise Value/Revenue
6.10
Enterprise Value/EBITDA
28.13
Financial Highlights
Profitability and Income Statement
Profit Margin
11.37%
Return on Assets (ttm)
2.05%
Return on Equity (ttm)
2.29%
Revenue (ttm)
3.41B
Net Income Avi to Common (ttm)
388M
Diluted EPS (ttm)
2.85
Balance Sheet and Cash Flow
Total Cash (mrq)
687M
Total Debt/Equity (mrq)
12.86%
Levered Free Cash Flow (ttm)
508.38M